Korean J Gastroenterol.  2015 Apr;65(4):261-263. 10.4166/kjg.2015.65.4.261.

Can Mucosal Impedance Differentiate Gastroesophageal Reflux Disease (GERD) from Non-GERD Conditions?

• Jeong ID

• KMID: 2373220
• DOI: http://doi.org/10.4166/kjg.2015.65.4.261

Abstract

No abstract available.

Reference

References

1. Ates F, Yuksel ES, Higginbotham T, et al. Mucosal impedance discriminates GERD from non-GERD conditions. Gastroenterology. 2015; 148:334–343.

2. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006; 101:1900–1920.

3. American Gastroenterological Association. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology. 2011; 140:1084–1091.

4. Bredenoord AJ, Weusten BL, Timmer R, Conchillo JM, Smout AJ. Addition of esophageal impedance monitoring to pH monitoring increases the yield of symptom association analysis in patients off PPI therapy. Am J Gastroenterol. 2006; 101:453–459.

5. Sifrim D, Mittal R, Fass R, et al. Review article: acidity and volume of the refluxate in the genesis of gastro-oesophageal reflux disease symptoms. Aliment Pharmacol Ther. 2007; 25:1003–1017.

6. Farré R, van Malenstein H, De Vos R, et al. Short exposure of oesophageal mucosa to bile acids, both in acidic and weakly acidic conditions, can impair mucosal integrity and provoke dilated in-tercellular spaces. Gut. 2008; 57:1366–1374.

7. Koek GH, Sifrim D, Lerut T, Janssens J, Tack J. Effect of the GABA(B) agonist baclofen in patients with symptoms and duode-no-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut. 2003; 52:1397–1402.

8. Savarino E, Zentilin P, Tutuian R, et al. The role of nonacid reflux in NERD: lessons learned from impedance-pH monitoring in 150 patients off therapy. Am J Gastroenterol. 2008; 103:2685–2693.

9. Zerbib F, Duriez A, Roman S, Capdepont M, Mion F. Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors. Gut. 2008; 57:156–160.

10. Farré R, Blondeau K, Clement D, et al. Evaluation of oesophageal mucosa integrity by the intraluminal impedance technique. Gut. 2011; 60:885–892.

11. Lehman MB, Clark SB, Ormsby AH, Rice TW, Richter JE, Goldblum JR. Squamous mucosal alterations in esophagectomy specimens from patients with end-stage achalasia. Am J Surg Pathol. 2001; 25:1413–1418.

12. Kjellin AP, Ost AE, Pope CE 2nd. Histology of esophageal mucosa from patients with achalasia. Dis Esophagus. 2005; 18:257–261.

13. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut. 2009; 58:295–309.

14. Hershcovici T, Fass R. Step-by-step management of refractory gastresophageal reflux disease. Dis Esophagus. 2013; 26:27–36.

15. Fujiwara Y, Arakawa T, Fass R. Gastroesophageal reflux disease and sleep. Gastroenterol Clin North Am. 2013; 42:57–70.

16. Wilder-Smith C, Röhss K, Bokelund Singh S, Sagar M, Nagy P. The effects of dose and timing of esomeprazole administration on 24-h, daytime and night-time acid inhibition in healthy volunteers. Aliment Pharmacol Ther. 2010; 32:1249–1256.

17. Mainie I, Tutuian R, Shay S, et al. Acid and nonacid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory im-pedance-pH monitoring. Gut. 2006; 55:1398–1402.